Literature DB >> 25494541

Generation and characterization of a single-chain anti-EphA2 antibody.

Yehuda Goldgur1, Petri Susi, Eveliina Karelehto, Hanna Sanmark, Urpo Lamminmäki, Elisa Oricchio, Hans-Guido Wendel, Dimitar B Nikolov, Juha P Himanen.   

Abstract

Recombinant antibody phage library technology provides multiple advantages, including that human antibodies can be generated against proteins that are highly conserved between species. We used this technology to isolate and characterize an anti-EphA2 single-chain antibody. We show that the antibody binds the antigen with 1:1 stoichiometry and has high specificity for EphA2. The crystal structure of the complex reveals that the antibody targets the same receptor surface cavity as the ephrin ligand. Specifically, a lengthy CDR-H3 loop protrudes deep into the ligand-binding cavity, with several hydrophobic residues at its tip forming an anchor-like structure buried within the hydrophobic Eph pocket, in a way similar to the ephrin receptor-binding loop in the Eph/ephrin structures. Consequently, the antibody blocks ephrin binding to EphA2. Furthermore, it induces apoptosis and reduces cell proliferation in lymphoma cells lines. Since Ephs are important mediators of tumorigenesis, such antibodies could have applications both in research and therapy.

Entities:  

Keywords:  Crystal structure; eph receptor; single-chain antibody

Mesh:

Substances:

Year:  2014        PMID: 25494541      PMCID: PMC4335687          DOI: 10.3109/08977194.2014.983225

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  22 in total

1.  Crystal structure of an Eph receptor-ephrin complex.

Authors:  J P Himanen; K R Rajashankar; M Lackmann; C A Cowan; M Henkemeyer; D B Nikolov
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

2.  Small rearrangements in structures of Fv and Fab fragments of antibody D1.3 on antigen binding.

Authors:  T N Bhat; G A Bentley; T O Fischmann; G Boulot; R J Poljak
Journal:  Nature       Date:  1990-10-04       Impact factor: 49.962

Review 3.  Overview of monoclonal antibodies in cancer therapy: present and promise.

Authors:  M Stern; R Herrmann
Journal:  Crit Rev Oncol Hematol       Date:  2005-04       Impact factor: 6.312

4.  An open letter to our readers on the use of antibodies.

Authors:  Clifford B Saper
Journal:  J Comp Neurol       Date:  2005-12-26       Impact factor: 3.215

5.  Commercial antibodies: the good, bad, and really ugly.

Authors:  John R Couchman
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

Review 6.  Monoclonal antibodies based on hybridoma technology.

Authors:  Hisanori Yagami; Hiroshi Kato; Kanta Tsumoto; Masahiro Tomita
Journal:  Pharm Pat Anal       Date:  2013-03

Review 7.  Antibody therapeutics in cancer.

Authors:  Mark X Sliwkowski; Ira Mellman
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

8.  The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.

Authors:  Elisa Oricchio; Gouri Nanjangud; Andrew L Wolfe; Jonathan H Schatz; Konstantinos J Mavrakis; Man Jiang; Xiaoping Liu; Joanne Bruno; Adriana Heguy; Adam B Olshen; Nicholas D Socci; Julie Teruya-Feldstein; Frances Weis-Garcia; Wayne Tam; Rita Shaknovich; Ari Melnick; Juha P Himanen; R S K Chaganti; Hans-Guido Wendel
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

9.  Monoclonal antibodies as diagnostics; an appraisal.

Authors:  M Z Siddiqui
Journal:  Indian J Pharm Sci       Date:  2010-01       Impact factor: 0.975

10.  BALBES: a molecular-replacement pipeline.

Authors:  Fei Long; Alexei A Vagin; Paul Young; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-12-05
View more
  5 in total

Review 1.  Therapeutic potential of targeting the Eph/ephrin signaling complex.

Authors:  Nayanendu Saha; Dorothea Robev; Emilia O Mason; Juha P Himanen; Dimitar B Nikolov
Journal:  Int J Biochem Cell Biol       Date:  2018-10-19       Impact factor: 5.085

2.  SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.

Authors:  Joseph H Choe; Payal B Watchmaker; Milos S Simic; Ryan D Gilbert; Aileen W Li; Nira A Krasnow; Kira M Downey; Wei Yu; Diego A Carrera; Anna Celli; Juhyun Cho; Jessica D Briones; Jason M Duecker; Yitzhar E Goretsky; Ruth Dannenfelser; Lia Cardarelli; Olga Troyanskaya; Sachdev S Sidhu; Kole T Roybal; Hideho Okada; Wendell A Lim
Journal:  Sci Transl Med       Date:  2021-04-28       Impact factor: 19.319

3.  The Ephb2 Receptor Uses Homotypic, Head-to-Tail Interactions within Its Ectodomain as an Autoinhibitory Control Mechanism.

Authors:  Yan Xu; Dorothea Robev; Nayanendu Saha; Bingcheng Wang; Matthew B Dalva; Kai Xu; Juha P Himanen; Dimitar B Nikolov
Journal:  Int J Mol Sci       Date:  2021-09-28       Impact factor: 5.923

4.  Isolation and characterization of phage display-derived scFv antibodies against human parechovirus 1 VP0 protein.

Authors:  Eero Hietanen; Lav Tripathi; Eeva-Christine Brockmann; Pirjo Merilahti; Urpo Lamminmäki; Petri Susi
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

Review 5.  Targeting EphA2 in cancer.

Authors:  Ta Xiao; Yuhang Xiao; Wenxiang Wang; Yan Yan Tang; Zhiqiang Xiao; Min Su
Journal:  J Hematol Oncol       Date:  2020-08-18       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.